Merrimack Provides Business Update and Reports 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Merrimack Pharmaceuticals (MACK) PT Lowered to $12 at Baird
March 12, 2018 11:10 AM EDTBaird lowered its price target on Merrimack Pharmaceuticals (NASDAQ: MACK) to $12.00 (from $15.00) while maintaining a Neutral rating.
Analsyt Michael Ulz said while multiple readouts are expected later this year, they are incrementally cautious and reiterate our Neutral rating.
... More